Tumors that developed in carriers of HRR P/LP variants harbored more prevalent somatic TP53 variants, regardless of cancer type, and generally had fewer variants in driver genes (eg, PTEN, KRAS, and ERBB2 in ovarian cancer and ARID1A in both ovarian and endometrial cancer). This evidence concerns the gene KRAS and cancer.